Literature DB >> 24037608

Sebaceous carcinoma in Japanese patients: clinical presentation, staging and outcomes.

Akihide Watanabe1, Michelle T Sun, Adnan Pirbhai, Kosuke Ueda, Nobutada Katori, Dinesh Selva.   

Abstract

AIM: To describe the clinical features, management and correlation of the American Joint Committee on Cancer tumour node metastasis (TNM) staging for eyelid carcinoma with outcomes in Japanese patients with sebaceous carcinoma.
METHODS: Multicentre retrospective review of 63 Japanese patients. Tumours were staged using the American Joint Committee on Cancer 7th edition TNM criteria.
RESULTS: A distinct mass was the initial presentation in 94% and correct initial diagnosis made in 57% patients. Most tumours (60%) presented at stage T2aN0M0. The remaining TNM stages were: T2bN0M0 (25%); T3aN0M0 (9%); T3bN0M0 (2%); T2bN1M0 (2%); T3bN1M1 (2%). Frozen section controlled excision was performed in 81%. One patient required an orbital exenteration. Median follow-up was 4.2 years. Local recurrence occurred in four patients treated with frozen section controlled excision. Five patients had regional nodal metastases, two of which had T2aN0M0 lesions. T3a tumours and greater were significantly associated with local recurrence but not regional nodal metastasis. One patient died due to disease. One patient is alive with disease, and remaining patients were alive without disease at last follow-up.
CONCLUSIONS: In this Japanese cohort, an eyelid mass was the main clinical presentation of sebaceous carcinoma. Contrary to previous reports, T2a tumours smaller than 10 mm were associated with regional nodal metastases.

Entities:  

Keywords:  Orbit

Mesh:

Year:  2013        PMID: 24037608     DOI: 10.1136/bjophthalmol-2013-303758

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors:  Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

3.  Eyelid sebaceous carcinoma: Validation of the 8th edition of the American Joint Committee on cancer T staging system and the prognostic factors for local recurrence, nodal metastasis, and survival.

Authors:  Yun Hsia; Ching-Yuan Yeh; Yi-Hsuan Wei; Lily-Wei Chen; Shu-Lang Liao
Journal:  Eye (Lond)       Date:  2019-05-31       Impact factor: 3.775

4.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

5.  Rare malignant adnexal tumour of the skin involving distal phalanx of right thumb with co-existing primary lung cancer in a 72-year-old patient: A case report.

Authors:  Deepika Aggarwal; Vimal Jain
Journal:  Int J Surg Case Rep       Date:  2022-05-10

6.  Prognosis of eyelid sebaceous gland carcinoma based on the tumor (T) category of the American Joint Committee on Cancer (AJCC) classification.

Authors:  Swathi Kaliki; Adit Gupta; Mohammed Hasnat Ali; Anuradha Ayyar; Milind N Naik
Journal:  Int Ophthalmol       Date:  2016-02-01       Impact factor: 2.031

7.  Eyelid sebaceous gland carcinoma: Varied presentations and reconstruction outcome.

Authors:  Syed Ali Raza Rizvi; Md Shahid Alam; Kafil Akhtar
Journal:  Oman J Ophthalmol       Date:  2018 Jan-Apr

8.  Clinicopathological Analysis and Surgical Outcome of Eyelid Malignancies: A Study of 332 Cases.

Authors:  Syeed Mehbub Ul Kadir; Mukti Rani Mitra; Riffat Rashid; Murtuza Nuruddin; Md Kamrul Hassan Khan; Golam Haider; Mst Sayedatun Nessa
Journal:  J Skin Cancer       Date:  2022-02-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.